Hepato Formula Fosfatidilcolina N-Acetilcisteina Silimarina
Hepato Formula
Hepato
Formula - 700 mg, 1Fl. 300 mg x 30 Caps. + 1 Fl. 400 mg, 30 Caps.: 21 g
|
Analiza
Nutritiva: 4 Ingrediente = 700 mg
|
| Fosfatidilcolina
35% Concentratie tripla |
400
mg
|
/**
|
| N-Acetilcisteina |
100
mg
|
/**
|
| Silimarina (Silybum Marianum) extract standardizat
Silimarina 80% |
100 mg
|
/**
|
| Silimarina (Silybum Marianum) Folium |
100 mg |
/** |
1. Fosfatidilcolina cu avantaj in bolile cronice de ficat.
2. N-Acetilcisteina la pacienti cu hepatita cronica: Farmacocinetica
3. Silimarina in tratarea bolilor cronice hepatice.
4. Fosfatidilcolina un stimulator cerebral
5. Fosfatidilcolina 35% in tratamentul
de reducere a nivelului seric al colesterolului total in hipercolesterolemie
6. Fosfatidilcolina 35% are efect de
a reduce
valorile lipoproteinelor cu densitate joasa (colesterolul-LDL)
7. Fosfatidilcolina 35% in tratamentul
bolilor neorologice ca Alzheimer si Parkinson
8. Fosfatidilcolina 35% cu
inalta doza ca: Lecitina Suprema extr.standartizat de Fosfatidilcolina 35%
in boala Alzheimer, studiu randomizat, dublu-orb, placebo
controlat
| Creier sanatos |
Creier cu Alzheimer |
 |
 |
9. Fosfatidilcolina 35% in tratamentul
de scurta si lunga durata la boala Alzheimer studiu randomizat, dublu-orb,
placebo controlat
10. Fosfatidilcolina 35% cu functie
in
invatare si exercitiu de memorare la boala suspect de Alzheimer
11. Fosfatidilcolina
35% indicat ca cura de memorie pentru dementa sau declin
cognitiv
12. Fosfatidilcolina 35% creste concentratia
plasmatica de colina si reduce steatoza hepatica
13. Fosfatidilcolina 35% si Colina cu
inalta doza la pacienti cu boala Alzheimer
14. Fosfatidilcolina 35% si Colina in mentinerea
sanatatii umane si prevenirea bolilor
15. N-Acetilcisteina creste circulatia regionala a singelui in ficat inbunatateste
functia ficatului
la pacienti cu in timpul unui soc septic, studiu randomizat, dublu-orb,
placebo controlat
16. Acetilcisteina creste circulatia regionala a singelui in ficat in timpul
de soc endotoxic
17. N-Acetilcisteina creste hemodinamica si transportul de oxigen la hepatita
fulminanta
18. N-Acetilcisteina creste hemodinamica si transportul de oxigen la disfunctia
hepatica
19. N-Acetilcisteina la pacienti cu hepatita cronica: Farmacocinetica
| N-Acetilcisteina la pacienti cu hepatita cronica: Farmacocinetica |
 |
Silimarina (Silybum Marianum)- foto Familia: Asteraceae/Compositaea
| Silimarina (Silybum Marianum) extract standardizat
Silimarina 80% din: Farmacia Naturala |
 |
| Silimarina cu puritate si concentratie de: Silimarina
80% |
 |
20. Silimarina extract standardizat: Silimarina 80%, un remarcabil antioxidant si
un protector hepatic
21. Silimarina un antioxidant flavonoid, structura,
functie si uz clinic
22. Efect stimulator Silimarina, Silibinina si Silicristina
la celulele de rinichi
23. Silimarina impreuna cu izomerul sau Silibina
cu efect la pacienti cu colecistectomie
24. Silimarina inhiba peroxidarea lipidica
25. Silimarina antioxidant efectiv in tratamentul
de hiperinsulinemie la pacienti diabetici
26. Consumul de Silimarina in tratarea bolilor cronice
hepatice
27. Silimarina in prevenirea de ciroza hepatica
28. Silimarina indicat in infectii de hepatite virale
acute, studiu randomizat, dublu-orb, placebo controlat
29. Silimarina indicat in hepatite si hepatite
cronice, studiu randomizat, dublu-orb, placebo controlat
30. Silimarina un antioxidant, flavonoid si lignani
reduce valorile ale lipoproteinelor cu densitate joasa (colesterolul-LDL)
la persoane cu hipercolesterolemie si hiperlipoproteinemie
31. Silimarina indicat in hiperinsulinemie la pacienti cu ciroza hepatica
si diabet zaharat
32. Silimarina indicat in ciroza hepatica, studiu
randomizat, dublu-orb, placebo controlat
33. Silimarina indicat in ciroza hepatica si hepatita
alcolica, studiu randomizat, dublu-orb, placebo controlat
34. Silimarina reduce progresia de fibroza hepatica
35. Silmarina si Silibinina izomer al silimarinei
inhiba invazia cancerului de plamin, reduce enzima urokinaza si metaloproteinaza
matricial-2
36. Silimarina inhiba activitatea de telomeraza si antigenul
specific prostatic, silibinina previne cancerul de prostata
37. Silibina izomer al silimarinei cu efect antiproliferativ
in maligne ginecologice si cancer mamar
38. Silimarina un natural antioxidant, flavonoid polifenolic
inhiba carcinogeneza in colon
39. Silimarina ca flavonoid cu efect in intoxicatia
de medicamente, studiu randomizat, dublu-orb, placebo controlat
40. Silimarina si Vitamina B complex in tratamentul
de boli cronice hepatice, sistematic reviu cu meta analiza
41. Silimarina extract cu efect imunostimulator
42. Silimarina in tratamentul de Alzheimer
43. Silimarina cu cu
efect la pacienti cu colestaza
44. Silimarina previne iradierea de raze ultraviolete
UV-A
45. Silimarina, Acid Alfa Lipoic si Seleniu ca antioxidanti in tratamentul
de hepatita C
Complex de Silimarina si Fosfatidilcolina 35 %
46. Studiu comparativ intre Silimarina si
complex de Silibina si Fosfatildilcolina in hepatita cronica activa, studiu randomizat, dublu-orb, placebo controlat
47. Interferon-Alpha si Ribavirina la pacienti cu hepatita C cronica, care nu raspunde
la tratamente anterioare, studiu randomizat dublu orb placebo controlat cu
studiu multi centru
48. Stabilizarea functiei hepatice cu Interferon-Alpha
si Ribavirina la terapia antivirala de ciroza progresiva
Recomandare la hepatita C:
- Interferon-Alpha 3 milioane U.I subcutan
de 3 ori pe saptamina
timp de 6 luni de zile
- Ribavirina 3 x 400 mg pe zi (1000 - 1200 mg pe zi) 6 luni de zile impartite
iar
ca tratament adjuvant:
- EGCG 50% 300 - 900 mg pe zi
- Garlic 3000 - 4000 mg pe zi
- Silimarina 200 mg - 500 mg pe zi
- Fosfatidilcolina
35% 400mg - 800 mg pe zi
- N-Acetilcisteina 500 mg - 1500 mg pe zi
- Acid Alfa Lipoic 250 mg - 500 mg pe zi
- Struguri Rosii OPC 95% 100 mg - 300 mg pe zi
- Melatonina 500 mcg - 6 mg inainte de culcare
- VITAMINA E 400 UI - 800 UI pe zi
Terapia Anti Aging:
 Anti-Aging-Systeme
- Formula AntiAging
Bibliografie - References: Referinte Hepato Formula
Informatii din bibliografia electronica la tema: Nutritie si sanatate
1. Hayashi H, Tanaka Y, Hibino H, Umeda Y, Kawamitsu H, Fujimoto H, Amakawa T.
Beneficial effect of salmon roe phosphatidylcholine in chronic liver disease.
Current Medical Research Opinion. 1999;15(3):177-184.
2. Hayashi H, Tanaka Y, Hibino H, Umeda Y, Kawamitsu H, Fujimoto H, Amakawa T.
Beneficial effect of salmon roe phosphatidylcholine in chronic liver disease.
Current Medical Research Opinion. 1999;15(3):177-184.
3. Tanasescu, C., S. Petrea,
et al. (1988). "Use
of the Romanian product Silimarina in the treatment
of chronic liver diseases." Med
Interne 26(4): 311-22.
- Sarre H, Experience in the treatment of chronic hepatopathies with silymarin,
Arzneim-Forsch 1971; 21:1209-12
- Luper S. A review of plants used in the treatment of liver disease: Part 1.
Altern Med
Rev 1998. 3:410-21.
- Bergner P. Botanical medicine: Silybum marianum and liver therapy. Townsend
Lett Doctors 1988. 61-2:348-9.
-
Hobbs C. Milk thistle: The liver herb. Loveland (CO): Interweave Press; 1994.
4. Harris CM, Dysken MW, Fovall P, Davis JM. Effect of lecithin on memory in
normal adults. American Journal of Psychiatry. 1983;140(8):1010-1012.
5. Simons LA, Hickie JB, Ruys J. Treatment of hypercholesterolaemia with oral
lecithin. Australia and New Zealand Journal of Medicine. 1977;7(3):262-266.
6. Spilburg CA, Goldberg AC, McGill JB, et al. Fat-free foods supplemented with
soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol.
Journal of the American Dietetic Association. 2003;103(5):577-581.
7. Barbeau A. Emerging treatments: replacement therapy with choline or lecithin
in neurological diseases. Canadian Journal of Neurological Sciences. 1978;5(1):157-160.
- Pomara N, Domino EF, Yoon H, Brinkman S, Tamminga CA, Gershon S. Failure of
single-dose lecithin to alter aspects of central cholinergic activity in Alzheimer's
disease. Journal of Clinical Psychiatry. 1983;44(8):293-295.
- Barbeau A. Lecithin in Parkinson's disease. Journal of Neural Transmission
Supplement. 1980;(16):187-193.
8. Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled
trial of high-dose lecithin in Alzheimer's disease. Journal of Neurology, Neurosurgery,
and Psychiatry. 1985;48(8):736-742.
- Perryman KM, Fitten LJ. Delayed matching-to-sample performance during a double-blind
trial of tacrine (THA) and lecithin in patients with Alzheimer's disease. Life
Science. 1993;53(6):479-486.
- Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS. Efficacy of
tacrine and lecithin in mild to moderate Alzheimer's disease: double-blind trial.
British Medical Journal 1994;308(6933):879-883.
9. Fitten LJ, Perryman KM, Gross PL, Fine H, Cummins J, Marshall C. Treatment
of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind
study. American Journal of Psychiatry. 1990;147(2):239-242.
10. Brinkman SD, Smith RC, Meyer JS, et al. Lecithin and memory training in suspected
Alzheimer's disease. Journal of Gerontology. 1982;37(1):4-9.
11. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane
Database System Review. 2000;(4):CD001015.
- Phosphatidylcholine.
Altern Med Rev. 2002 Apr;7(2):150-4.
- "Brain-specific" nutrients: a memory
cure McDaniel MA, Maier SF,
Einstein GO. Nutrition. 2003 Nov-Dec;19(11-12):957-75.
12. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline
and decreases hepatic steatosis in long-term total parenteral nutrition patients.
Gastroenterology. 1992;102(4 Pt 1):1363-1370.
13. The effect of long-term high dose lecithin on erythrocyte choline transport
in Alzheimer patients. Uney JB, Jones GM, Rebeiro A, Levy R Biol Psychiatry 1992
Mar 15
31:6 630-3
14. Lecithin and choline in human health and disease. Canty DJ, Zeisel SH Nutr
Rev 1994 Oct 52:10 327-39
- Blusztajn JK.Choline, a vital amine. Department of Pathology, Boston University
School of Medicine, Boston, MA 02118, USA. jbluszta@bu.edu. Science. 1998 Aug
7;281(5378):794-5.
15. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann A, Spies
C: N-acetylcysteine increases liver blood flow and improves liver function in
septic shock patients: results of a prospective, randomized, double-blind study.
Crit Care Med 2000, 28:3799-3807.
- Ott P: Effects of N-acetylcysteine on hepatic blood flow and function [letter].
Crit Care Med 1998, 26:415.
16. Zhang H, Spapen H, Nguyen DN, Rogiers P, Bakker J, Vincent JL: Effects of
N-acetyl-L-cysteine on regional blood flow during endotoxic shock. Eur Surg Res
1995, 27:292-300.
17. Harrison PM, Wendon JA, Gimson AES, et al. Improvement by acetylcysteine
of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med.
1991; 324:1852-1857.
18. Devlin J, Ellis AE, McPeake J, Heaton N, Wendon JA, Williams R: N-acetylcysteine
improves indocyanine green extraction and oxygen transport during hepatic dysfunction.
Crit Care Med 1997, 26:236-242.
19.Jones AL, Jarvie DR, Simpson D, et al. Pharmacokinetics of N-acetylcysteine
are altered in patients with chronic liver disease. Aliment Pharmacol Ther. 1997;
11:787-791.
20. Tenney L. Milk thistle: A remarkable flavonoid antioxidant and liver protectant.
Pleasant Grove (UT): Woodlands
Publications; 1995.
- Lapis, K., A. Jeney, et al. (1986). "Experimental
studies on the effect
of hepatoprotective compounds." Tokai J Exp Clin Med 11(Suppl): 135-45.
- Feher J, Lengyel G, Blazovics A. Oxidative stress in the liver and biliary
tract diseases. Scand J Gastroenterol Suppl 1998. 228:38-46.
21. Miller AL. Antioxidant flavonoids: Structure, function and clinical usage.
Altern Med Rev 1996. 1:103-11.
22. Sonnenbichler J et al, Stimulatory effects of silibinin and silicristin from
the milk thistle
Silybum marianum on kidney cells, J Pharmacol Exp Ther 1999;290(3):1375-83
23. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following
administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung
1992. 42:964-8.
24. Bindoli A, Cavallini L, Siliprandi N. Inhibitory action of silymarin of lipid
peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol
1977. 26:2405-9.
25. Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment
with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous
insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol
1997. 26:871-9.
26. Mira ML, Azevedo MS, Manso C. The neutralization of hydroxyl radical by silibin,
sorbinil and bendazac. Free Radic Res Commun 1987. 4:125-9.
- Valenzuela A, Guerra R, Videla LA. Antioxidant properties of the flavonoids
silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated
hydroxytoluene. Planta Med 1986. 6:438-40.
- Dehmlow C, Murawski N, de Groot H. Scavenging of reactive oxygen species and
inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci
1996. 58:1591-600.
- Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural
antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits
T-lymphocyte function at low doses but stimulates inflammatory processes at high
doses. Planta Medica. 2003;69(1):44-49.
27. Mourelle, M., P. Muriel, et al. (1989). "Prevention
of CCL4-induced
liver cirrhosis by silymarin." Fundam Clin Pharmacol 3(3): 183-91.
28. Tkacz B, Dworniak D. Sylimarol in the treatment of acute viral hepatitis.
Pol. Wiad Lek 1983. 36:613-6.
- Saba P, Mignani E, Pagliai, et al. Efficacy of silymarin treatment of acute
virus hepatitis. Ita. Epatologia 1979. 25:277-81.
- Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis
Report of a controlled trial
author's transl. Ger. Med Klin 1977. 72:513-8.
- Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect
of silymarin in the treatment of acute viral hepatitis, carried out at two medical
centres author's transl. Ger.
Med Klin 1978. 73:1060-5.
29. Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterology Nursing.
2001;24(2):95-97.
- Kiesewetter E, Leodolter I, Thaler H. Results of two double-blind studies on
the effect of silymarine in chronic hepatitis author's transl. Ger. Leber Magen
Darm 1977. 7:318-23.
30. Svagera Z, Skottova N, Vana P, et al. Plasma lipoproteins in transport of
silibinin, an antioxidant flavonolignan from Silybum marianum. Phytotherapy Research.
2003;17(5):524-530.
- Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L. Effects of polyphenolic
fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets.
Pharmacology Research. 2003;47(1):17-26.
- Skottova N, Krecman V. Silymarin as a potential hypocholesterolaemic drug.
Physiology Research. 1998;47(1):1-7.
- Krecman V, Silymarin inhibits the development of diet-induced hypercholesterolemia
in rats, Planta Med 1998;64(2):138-42
- Krecman V, Skottova N, Walterova D, Ulrichova J, Simanek V. Silymarin inhibits
the development of diet-induced hypercholesterolemia in rats. Planta Medica.
1998;64(2):138-142.
- Somogyi A, Ecsedi GG, Blazovics A, Miskolczi K, Gergely P, Feher J. Short term
treatment of type II sic with silymarin. Acta Medica Hungaria. 1989;46(4):289-295.
31. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M.
Study of the hypoglycaemic sic activity of Fraxinus excelsior and Silybum marianum
in an animal model of type 1 diabetes mellitus. Journal of Ethnopharmacology.
2004;91(2-3):309-316.
- Velussi M, Cernigoi AM, Viezzoli L, et al. . Silymarin reduces hyperinsulinemia,
malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients.
Curr Ther Res Clin Exp 1993. 53:535-45.
32. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of
silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989.
9:105-13.
- Benda L, Dittrich H, Ferenzi P, et al. The influence of therapy with silymarin
on the survival rate of patients with liver cirrhosis author's transl. Ger. Wien
Klin Wochenschr 1980. 92:678-83.
- Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological
alterations of the liver. A double-blind controlled study. Scand J Gastroenterol
1982. 17:517-21.
- Muriel P, Mourelle M. The role of membrane composition in ATPase activities
of cirrhotic rat liver: effect of silymarin. Journal of Applied Toxicology. 1990;10(4):281-284.
- Pares A, Plancs R, Torres M, et al. Effects of silymarin in alcoholic patients
with cirrhosis of the liver: results of a controlled, double-blind, randomized
and multicenter trial. J Hepatol 1998;28:615–21.
33. Trinchet JC, Coste T, Levy VG, et al. A randomized double blind trial of
silymarin in 116 patients with alcoholic hepatitis. Fre. Gastroenterol Clin Biol
1989. 13:120-4.
- Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, et al. Effects
of silymarin in alcoholic patients with cirrhosis of the liver: results of a
controlled, double-blind, randomized and multicenter trial. Journal of Hepatology.
1998. 28(4):615-621.
- Feher J, Deak G, Muzes G, et al. Liver-protective action of silymarin therapy
in chronic alcoholic liver diseases. Hun. Orv
Hetil 1989. 130:2723-7.
- Bunout D, Hirsch S, Petermann M, et al. Controlled study of the effect of silymarin
on alcoholic liver disease. Spa. Rev Med
Chil 1992. 120:1370-5.
34. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression
of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology.
2003;37(4):336-339.
35. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion
of human lung cancer cells via decreased productions of urokinase-plasminogen
activator and matrix metalloproteinase-2. Molecular Carcinogens. 2004;40(3):143-149.
- Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of
the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994.
27:105-12.
36. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase
activity and secretion of prostate specific antigen by silibinin in prostate
cancer cells. Journal of Urology. 2004;171(5):1934-1938.
- Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Current Cancer
Drug Targets. 2004;4(1):1-11.
Zi X et al, Silibinin decreases prostate-specific antigen with cell growth inhibition
via G1 arrest, leading to differentiation of prostate carcinoma cells: implications
for prostate cancer intervention, Proc Natl Acad Sci U S A 1999;96(13):7490-5
- Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative
and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002;53(3):211-217.
- Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human
prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition
and apoptotic death. International Journal of Cancer. 2003;106(5):699-705.
37. Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect
of silybin on gynaecological sic malignancies: synergism with cisplatin and doxorubicin.
European Journal of Cancer. 1996;32A(5):877-882.
- Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of
silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin
against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncology Reports. 2004;11(2):493-499.
- Zi X et al, Anticarcinogenic effect of a flavonoid antioxidant, silymarin,
in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase
in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent
kinases and associated cyclins, Clin Cancer Res 1998;4(4):1055-64
38. Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H. Silymarin,
a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced
colon carcinogenesis in male F344 rats. International Journal of Cancer. 2002;101(5):461-468.
39. Davila, J.C., Lenherr, A., and Acosta, D. "Protective
Effect of Flavonoids
on Drug-Induced Hepatotoxicity In Vitro." Toxicology. 1989. 57(3):267-86.
- Tuchweber B, Sieck R, Trost W. Prevention by silibinin of phalloidin induced
hepatotoxicity. Toxicol Appl Pharmacol
1979;51:265–75.
- Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans
from Silybum marianum fruits. Planta Medica 1984;50:248–50.
- Garciapina, M.P., Perez-Alvarez, V., and Mourelle, M. "Silymarin
Protects
Against Paracetamol-Induced Lipid Peroxidation and Liver Damage." Journal
of Applied Toxicology. 1992. 12(6):439-42.
- Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in
the perfused rat liver. Arzneim-Forsch Drug Res 1980;30:452–4.
- Palasciano G, Portinascasa P, Palmieri V, et al. The effect of silymarin on
plasma levels of malondialdehyde in patients receiving long-term treatment with
psychotropic drugs. Curr Ther Res 1994;S5:S37–45.
- Fintelmann V, Albert A. Double blind trial of silymarin sodium in toxic liver
damage. Ger. Therapiewoche 1980. 30:5589-94.
- Magula D, Galisova Z, Iliev N, et al. Effect of silymarine and Fumaria alkaloids
in the prophylaxis of drug-induced liver injury during antituberculotic treatment.
Slo. Stud Pneumol Phtiseol 1996. 56:206-9.
40. Studlar M. Treatment of chronic liver disease with silymarin plus B-group
vitamins. Ger. Therapiewoche 1985. 35:3375-8.
- Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the
treatment of liver disease: a systematic review and meta-analysis. American Journal
of Medicine. 2002;113(6):506-515.
- Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy
of liver disease. Am J Gastroenterol
1998. 93:139-43.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver
diseases. Drugs. 2001;61(14):2035-2063.
- Bode JC. . Re: Flora, et al. Silymarin for the therapy of liver disease. Am
J Gastroenterol 1999. 94:545-6.
41. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur
DS. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Medical
and Science Monitor. 2002;8(11):BR439-BR443.
42. Allain H, Shuck S, Lebreton S, et al. Aminotransferase levels and silymarin
in de novo tacrine-treated patients with alzheimer's disease. Dement Geriatr
Cogn Disord 1999. 10:181-5.
43. Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, et al. Beneficial effects of
silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in
isolated hepatocyte couplets. Hepatology. 2001;34(2):329-339.
44. Li LH, Wu LJ, Zhou B, et al. Silymarin prevents UV irradiation-induced A375-S2
cell apoptosis. Biology and Pharmacology Bulletin. 2004;27(7):1031-1036.
- Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet
radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine
dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis.
2004;25(8):1459-1465.
45. Berkson, B. M. (1999). "A conservative
triple antioxidant approach to the treatment of hepatitis C. Combination of alpha
lipoic acid (thioctic acid),
silymarin,
and selenium: three case histories." Med Klin 94 Suppl 3: 84-9.
46. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A
pilot study of the liver protective effect of silybin-phosphatidylcholine complex
(idb1016) in chronic active hepatitis. International Journal of Clinical Pharmacology,
Therapy, and Toxicology. 1993. 31(9):456-460.
- Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a
silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab
Pharmacokinet 1990. 15:333-8.
- Marcelli R, Bizzoni P, Conte D, et al. Randomized controlled study of the efficacy
and tolerability of a short course of IdB 1016 in the treatment of chronic persistent
hepatitis. Eur Bull Drug Res 1992. 1:131-5.
- Orlando R, Fragasso A, Lampertico M, et al. . Silybin kinetics in patients
with liver cirrhosis: A comparative study of silybin-phosphatidilcholine complex
and silymarin. Med Sci Res 1990. 18:861-3.
- Pifferi G, Magistretti MJ. . A new bioavailable complex of silybin: Part II.
Pharmacol Res 1993. 27:125-6.
47. Pol S, Couzigou
P, Bourlière
M, Abergel A, Combis JM, Larrey D, Tran A, Moussalli J, Poupon R, Berthelot P,
Bréchot C. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha
alone in patients with chronic hepatitis C who were non-responders to a previous
treatment. Multicenter Study Group under the coordination of the Necker Hospital,
Paris, France. Assistance Publique/Hôpitaux de Paris, Necker, France. J
Hepatol. 1999 Jul;31(1):1-7.
48. Tarantino G, Gentile A, Capone D, Basile V, Tarantino M, Di Minno MN, Cuocolo
A, Conca P. Does protracted antiviral therapy impact on HCV-related liver cirrhosis
progression Department of Clinical and Expermtal Medicine, Federico II University
Medical School of Naples,Via S. Pansini, 5, Naples 80131, World J Gastroenterol.
2007
Sep 28;13(36):4903-8.
Parerea din pasajele acestui site nu a fost independent cercetate sau confirmate.
|
Fosfatidilcolina cu avantaj in bolile cronice de ficat.
